Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 11/20 | 0.32 |
| ▸ | KDR | P35968 | 8/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902990 | 0.84 | SCN5A (0.43) | TGFBR1 | |
| SCHEMBL5315974 | 0.83 | TGFBR1 (0.36) | TGFBR1PIK3CDKDM1A | |
| SCHEMBL5139070 | 0.78 | PIM1 (0.35) | TGFBR1PIK3CDKDM4EALDH1A1KDM1A | |
| SCHEMBL4902499 | 0.76 | TGFBR1 (0.46) | TGFBR1AAK1 | |
| SCHEMBL19806592 | 0.75 | TGFBR1 (0.54) | TGFBR1PIK3CDKDM1A | |
| SCHEMBL4904075 | 0.73 | NPC1 (0.43) | TGFBR1AAK1 | |
| SCHEMBL4894431 | 0.72 | KDM4E (0.44) | KDM4EALDH1A1 | |
| SCHEMBL4894244 | 0.68 | IDH1 (0.38) | AAK1 | |
| SCHEMBL4896435 | 0.68 | TGFBR1 (0.46) | TGFBR1 | |
| SCHEMBL5138589 | 0.67 | TGFBR1 (0.47) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | claimed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1786803-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | Biogen Idec MA, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2006026305-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | BIOGEN IDEC MA INC (US) | 2006-03-09 | — | — | WO | claimed |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | disclosed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1786803-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | Biogen Idec MA, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006026305-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | BIOGEN IDEC MA INC (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | TGFBR1, SMAD3, ALK | TGFBR1 1/4885PIK3CD 1078/4885KDM4E 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.